演題抄録

International Symposium

開催概要
開催回
第51回・2013年・京都
 

The role of cisplatin and weekly docetaxel in advanced nasopharyngeal cancer

演題番号 : IS3-4

[筆頭演者]
Myung-Ju Ahn:1 

1:Department of Medicine, Section of Hematology-Oncology, Sunkyunkwan University School of Medicine/Samsung Medical Center, Korea

 

Nasopharyngeal cancer(NPC) is the one of the rarer cancers worldwide. However, it is relatively prevalent in East-Asian countries. Most of patients present locally advanced disease and concurrent chemoradiotherapy is considered the main treatment modality due to high effectiveness of chemotherapy in NPC. In metastatic or recurrent NPC, cisplatin-based combination chemotherapy such as 5-FU and cisplatin is effective and widely used. Several phase II studies were conducted incorporating new agents such as docetaxel and paclitaxel instead of 5-FU. Docetaxel inhibits cancer cell growth by promoting the assembly and inhibition of microtubule depolymerization. The combination chemotherapy of docetaxel and cisplatin has proven efficacy with non-small cell lung cancer and recurrent or metastatic head and neck cancer. However, myelosuppression is one of the serious concerns with every 3 week schedule of docetaxel administration, especially in older patients. Based on these results, we conducted phase II study of cisplatin and weekly docetaxel combination therapy as first-line treatment in patients with recurrent or metastatic NPC to determine efficacy and toxicity. Patients received 60mg/m2 of cisplatin on Day 1 and 35mg/m2 of docetaxel on Day 1 and 8 every 21 days. 47 patients were enrolled and 6 patients (12.8%) achieved complete response and 27 (57.4%) showed partial response with an objective response rate of 70.2%. The median progression free survival and overall survival were 9.6 months and 28.5 months, respectively. The grade 3 adverse events include stomatitis (1.2%) and neutropenia (0.8%) and anemia (0.8%) and infection (0.8%) and diarrhea (0.8%). There was no treatment related death. These results showed cisplatin and weekly docetaxel is highly effective and few toxicity as first-line chemotherapy in patients with recurrent or metastatic NPC.

前へ戻る